ArticleTurk patoloji dergisi2026
Digital Quantification of Progesterone Receptor Expression in Meningiomas: Associations with WHO Grade and Clinicopathological Features.
Article in Turk patoloji dergisi, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- CD34 and p16 expression in central nervous system solitary fibrous tumors: an exploratory clinicopathologic study.Journal of neuro-oncology · 2026Article
- Pan-TRK expression and NTRK gene aberrations in meningiomas: association with tumor grade and proliferative activity.The journal of pathology. Clinical research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveProgesterone receptor (PR) expression is a well-recognized marker in meningiomas, but manual immunohistochemical assessment is subjective and prone to variability. Digital pathology offers objective and reproducible quantification. Despite the availability of FDA-cleared digital PR scoring algorithms in some tumors like those of the breast, their implementation in meningiomas and systematic evaluation of their correlations with clinicopathological features remain scarce. MATERIAL AND
methodsWe retrospectively analyzed 129 meningioma cases resected between 2018 and 2024. Digital PR expression was quantified using the FDA-cleared Ventana uPath PR 1E2 algorithm, originally developed for breast carcinoma. Subsequently, tumors were stratified by age, sex, WHO grade, histological subtype, and localization, while Ki-67 index and mitotic counts were also recorded. Associations with digital PR H-scores were evaluated using non-parametric tests, correlation analysis, and ordinal logistic regression.
resultsDigital PR H-scores progressively decreased across WHO grades, with Grade 1 tumors showing the highest values, followed by Grade 2 and Grade 3 (p=0.002). PR expression was inversely correlated with proliferative markers, including Ki-67 index (ρ = -0.42, p < 0.001) and mitotic count (ρ = -0.35, p < 0.01). No significant differences were observed by age or sex. Convexity meningiomas tended to have higher scores than skull base and spinal tumors.
conclusionDigital PR H-score assessment confirmed the inverse association between PR expression and WHO grade, as well as its correlation with proliferative activity. Using an FDA-cleared algorithm originally developed for breast carcinoma, this method provides objective and reproducible evaluation in meningiomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.